Physicians with current and valid licenses in the United States, Canada, or Mexico who read any 3 of the selected continuing medical education (CME) articles in this issue of Archives of Neurology, complete the CME Evaluation Form, and fax it to the number or mail it to the address at the bottom of the CME Evaluation Form are eligible for category 1 CME credit. There is no charge.
The American Medical Association (AMA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The AMA designates this educational activity for up to 3 hours of category 1 CME credit per Archives of Neurology issue toward the AMA Physician's Recognition Award (PRA). Each physician should claim only those hours of credit that were actually spent in this educational activity.
Physicians with current and valid licenses in the United States, Mexico, or Canada are eligible for CME credit even if they live or practice in other countries. Physicians licensed in other countries are also welcome to participate in this CME activity. However, the PRA is only available to physicians licensed in the United States, Canada, or Mexico.
The Archives of Neurology provides new evidence for the practice of neurology, neurosurgery, and other specialties whose goal is to improve the neurological health of all people. Original contributions, neurological reviews, neurology and public health, and history of neurology are among the categories of articles published, but all contributions receive a sympathetic reading by the Chief Editor. The journal's editorial board sets the initial framework for the types of articles published, which is then modified by feedback from editors, external peer reviewers, authors, and readers. We are keen to receive submissions from practicing neurologists to provide new insight for colleagues.
We want our readers to assess each article critically; this CME activity is active, not passive. Does the article contribute in some way to the practice of neurology? How could you modify your practice style to incorporate what you have learned? How can you acquire more information, challenge the authors' conclusions, or verify what you have read? Which of the articles in each issue is least helpful in your quest for the best and most applicable evidence?
To earn 1 hour of category 1 CME credit, you should read any 3 of the CME articles listed below and complete the CME Evaluation Form. To earn 3 hours of credit, read all of the articles listed below and complete the CME Evaluation Form. The CME Evaluation Form must be submitted within 4 weeks of the issue date. A certificate awarding up to 3 hours of category 1 CME credit will be faxed or mailed to you; it is then your responsibility to maintain a record of credit received. Questions about CME credit processing should be directed to The Blackstone Group; tel: (312) 419-0400, ext 225; fax: (312) 269-1636.
One of our goals is to assess continually the needs of our readers so we may enhance the educational effectiveness of the Archives of Neurology. To achieve this goal, we need your help. You must complete the CME Evaluation Form to receive credit.
The articles listed below may be read for CME credit.
Experimental Neurotherapeutics: Leaps and Bounds
Educational Objective: To review advances in neurologic therapeutics.
Prospects for Vascular Endothelial Growth Factor Neurotherapeutics
Educational Objective: To explore the possible role of vascular endothelial growth factor in neurologic therapeutics.
Therapies for Movement Disorders
Educational Objective: To understand advances in therapy for movement disorders.
Treatment of Patients With Stroke
Educational Objective: To review advances in stroke therapeutics.
Viral Infections of the Nervous System, 2002: Update on Diagnosis and Treatment
Educational Objective: To learn about recent developments in diagnosis and treatment of viral infections of the nervous system.
Darts in the Dark Cure Animal, but Not Human, Brain Tumors
Educational Objective: To evaluate the benefits and shortcomings of treatments for brain tumors.
Current Immunotherapy for Demyelinating Diseases
Educational Objective: To assess immunotherapy for demyelinating diseases.
Therapy for the Epilepsies
Educational Objective: To appraise therapies for epilepsy.
Therapies for Disorders of the Neuromuscular Junction
Educational Objective: To understand current concepts in therapy for neuromuscular transmission disorders.
Friedreich Ataxia: Effects of Genetic Understanding on Clinical Evaluation and Therapy
Educational Objective: To explore potential therapies arising from genetic understanding of Friedreich ataxia.
Diabetic Demyelinating Polyneuropathy Responsive to Intravenous Immunoglobulin Therapy
Educational Objective: To examine intravenous immunoglobulin therapy in diabetic demyelinating polyneuropathy.
Demyelinating Neuropathy in Diabetes Mellitus
Educational Objective: To identify the development of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus.
Efficacy of Intravenous Immunoglobulin in Patients With IgG Monoclonal Gammopathy and Polyneuropathy
Educational Objective: To investigate intravenous immunoglobulin in IgG monoclonal gammopathy and polyneuropathy.
Methylprednisolone Acts on Peripheral Blood Mononuclear Cells and Endothelium in Inhibiting Migration Phenomena in Patients With Multiple Sclerosis
Educational Objective: To explore the mechanism of steroid therapy in multiple sclerosis.
Antiepileptic Drug–Induced Bone Loss in Young Male Patients Who Have Seizures
Educational Objective: To assess bone loss with antiepileptic therapy by dual-energy x-ray absorptiometry.
Plasma Homocysteine Levels, Cerebrovascular Risk Factors, and Cerebral White Matter Changes (Leukoaraiosis) in Patients With Alzheimer Disease
Educational Objective: To investigate stroke risk factors in Alzheimer disease by leukoaraiosis on computed tomographic scanning.
Lymphocyte Oxidative DNA Damage and Plasma Antioxidants in Alzheimer Disease
Educational Objective: To evaluate lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease.
Budipine Provides Additional Benefit in Patients With Parkinson Disease Receiving a Stable Optimum Dopaminergic Drug Regimen
Educational Objective: To learn about the efficacy of bupidine added to dopaminergic therapy in patients with Parkinson disease.
Refractory Nonmotor Symptoms in Male Patients With Parkinson Disease Due to Testosterone Deficiency: A Common Unrecognized Comorbidity
Educational Objective: To study the effect of testosterone on nonmotor features of Parkinson disease.
Risk Factors of Cognitive Impairment in HIV-1–Infected Persons With Different Risk Behaviors
Educational Objective: To identify risk factors of human immunodeficiency virus 1–related cognitive impairment.
Contribution of the Interleukin 4 Gene to Susceptibility to Subacute Sclerosing Panencephalitis
Educational Objective: To recognize host genetic factors in Japanese patients with subacute sclerosing panencephalitis.
RegionalN-Acetylaspartate Reduction in the Hippocampus Detected With Fast Proton Magnetic Resonance Spectroscopic Imaging in Patients With Alzheimer Disease
Educational Objective: To identify regional metabolic changes with fast proton spectroscopic imaging in patients with Alzheimer disease.
Brain Magnetic Resonance Imaging in Multiple-System Atrophy and Parkinson Disease: A Diagnostic Algorithm
Educational Objective: To evaluate magnetic resonance imaging in the differential diagnosis in multiple system atrophy with predominant parkinsonism and Parkinson disease.
Crossed Cerebellar Atrophy in Patients With Precocious Destructive Brain Insults
Educational Objective: To study crossed cerebellar atrophy in epilepsy secondary to early-life traumatic brain injury.
Familial Aggregation of Parkinson Disease: A Comparative Study of Early-Onset and Late-Onset Disease
Educational Objective: To investigate familial aggregation in early-onset and late-onset Parkinson disease.
Transient Visuospatial Disorder From Angiographic Contrast
Educational Objective: To learn about transient visuospatial disorder following angiographic contrast.
Autopsy-Proven, Sporadic Pick Disease With Onset at Age 25 Years
Educational Objective: To understand that Pick disease may present in young adults with behavioral problems.
CytochromecOxidase Deficiency Due to a NovelSCO2Mutation Mimics Werdnig-Hoffmann Disease
Educational Objective: To read about a novel SCO2 mutation with spinal cord involvement mimicking spinal muscular atrophy.
After you have read any 3 (to earn 1 hour of category 1 CME credit) or all (to earn 3 hours of credit) of these articles, please complete the CME Evaluation Form.
Archives of Neurology Reader's Choice: Continuing Medical Education. Arch Neurol. 2002;59(5):878-880. doi:10.1001/archneur.59.5.878